Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Toll Free Number
1-888-577-8839
Trialsites@merck.com


Study Location:

Skip to Main Content

Keep up to date

Sign up for news and information about taking part and shaping research.

English | Cymraeg
Be Part of Research - Trial Details - A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Recruiting

Open to: All Genders

Age: 18 Years - N/A

Medical Conditions

Melanoma


This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.


The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2023 Oct 2029

Interventional

Intervention Type : Biological
Intervention Description : IM injection

Intervention Arm Group : V940 + Pembrolizumab

Intervention Type : Biological
Intervention Description : IV infusion

Intervention Arm Group : Placebo + Pembrolizumab;V940 + Pembrolizumab

Intervention Type : Other
Intervention Description : IM injection

Intervention Arm Group : Placebo + Pembrolizumab



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University College London Hospital ( Site 1807)
    London
    London, City Of
    NW1 2PG
  • Norfolk and Norwich University Hospitals NHS Foundation Trust ( Site 1813)
    Cringleford
    England
    NR4 7UY
  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1804)
    London
    Kensington And Chelsea
    SW3 6JJ
  • Bristol Haematology and Oncology Centre ( Site 1811)
    Bristol
    Bristol, City Of
    BS2 8ED
  • Addenbrooke's Hospital ( Site 1800)
    Cambridge
    Cambridgeshire
    CB2 2QQ
  • The Churchill Hospital ( Site 1805)
    Oxford
    Oxfordshire
    OX3 7LE
  • Western General Hospital ( Site 1806)
    Edinburgh
    Midlothian
    EH4 2XU
  • The Christie NHS Foundation Trust ( Site 1814)
    Manchester
    m20 4bx


The study is sponsored by Merck Sharp & Dohme LLC and funded by ModernaTX, Inc..




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05933577
Last updated 23 April 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.